Supplementary Table 2 Pharmacokinetic parameters[a] of irinotecan and its main active metabolite SN-38 when irinotecan was administered as a 1.5-h intravenous infusion (100 mg/m^2) alone on cycle 1 day 1 or in combination with veliparib on cycle 2 day 8

	Cycle/day	n	T_{max} (h)	C_{max} (ng/ml)	AUC_{last} (ng/ml*h)	$AUC_{0-\infty}$ (ng/ml*h)	$T_{1/2}$ (h)	CL (L/h/m^2)	V_{ss} (L/m^2)
Irinotecan									
	1/1	34	1.5±0.2 (12%)	1079±344 (32%)	5205±1783 (34%)	5282±1831 (35%)	7.7±1.1 (15%)	20±5 (25%)	150±37 (25%)
	2/8	23	1.5±0.2 (14%)	823±246 (30%)	4091±1072 (26%)	4155±1093 (26%)	7.6±1.0 (14%)	25±7 (26%)	182±59 (33%)
SN-38									
	1/1	34	2.0±0.9 (47%)	11±5 (48%)	90±49 (54%)	112±61 (54%)	13.0±10.6 (82%)		
	2/8	23	1.9±1.0 (53%)	10±4 (41%)	68±33 (49%)	92±56 (61%)	12.6±12.1 (96%)		

[a] Pharmacokinetic parameters were estimated using non-compartmental analysis with WinNonlin (Pharsight). Data are expressed as the mean ± standard deviation with coefficient variation in the parenthesis.

Abbreviations: C_{max}, maximum plasma concentration; T_{max}, time to achieve C_{max}; AUC_{last}, area under the plasma concentration time curve from time 0 to the last sampling time point; $AUC_{0-\infty}$, area under the plasma concentration time curve from time 0 to infinity; $T_{1/2}$, terminal elimination half-life; CL, clearance; V_{ss}, volume of distribution at steady-state.